PAVmed is a medical device company employing a business model to bring innovative products from concept to commercialization with speed and capital efficiency, while enhancing and accelerating value creation.
PAVmed is building a deep pipeline of products encompassing a broad spectrum of clinical areas possessing attractive regulatory pathways and market opportunities currently exceeding $4 billion. The company currently has five lead products to provide multiple near-term value creation opportunities
The Company is led by a team of accomplished medical device entrepreneurs. The leadership team has previously successfully implemented its unique business model of creating value with modest capital investment in four single-product companies, each of which rapidly advanced towards commercialization. Two of these four products have been cleared and commercialized, while two products are currently undergoing FDA review. PAVmed leverages this unique business model.
By establishing a long-term multi-product company with access to public capital, the company plans to build an expanding pipeline of innovative products across a range of specialties and clinical conditions.
Featured Press Releases
6/23/17 4:51 pm EDTNEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly differentiated, multiproduct medical device company, today announced that on June 23, 2017, the Securities and Exchange Commission declared effective PAVmed’s registration statement on Form S-1 relating to resale by certain selling securityholders of certain shares and warrants issued and issuable from the Company’s previously announced preferred unit offering. PAVmed registered these securities tomore...
6/22/17 4:01 pm EDTNEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly differentiated, multiproduct medical device company, today announced that the Company will join the Russell Microcap® Index at the conclusion of the Russell Indexes’ annual reconstitution, effective after the U.S. market opens on June 26, 2017, according to a preliminary list of additions posted June 9, 2017 and again on June 16, 2017. Membership in the Russell Microcap® Index providesmore...
5/22/17 4:05 pm EDTNEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly differentiated, multiproduct medical device company, today announced financial results for the three months ended March 31, 2017 and provided a business update. “During the first quarter we continued to make solid progress in advancing our growth strategy and multiproduct pipeline towards commercialization, utilizing our capital- and time-efficient business model,” said Lishan Aklog, M.D.,more...